Phase III trial is designed to assess the effectiveness of the new intervention and, thereby, its value in clinical practice. It is randomized controlled multicenter trials on large patient groups (300–3,000 or more) and is aimed at being the definitive assessment of how effective the drug is, in comparison with current gold standard treatment.